Novo Nordisk is playing catch-up in the GLP-1 race.

Eli Lilly will allow a limited number of patients early access to retatrutide, its next-generation weight loss drug, before ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after the stock rebounded following a decline the previous week. The stock had dropped sharply the ...

There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.

Eli Lilly just posted its fourth straight earnings beat and raised guidance again, but the real question is whether a next-generation obesity drug still sitting below Wall Street's radar could push ...

The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal ...

As Lilly widens its lead in the obesity race, Novo is still racing to win back market share and restore investor confidence ...

Eli Lilly on Wednesday reported better-than-expected quarterly results and raised its full-year guidance as the company's ...

The Eli Lilly logo appears on a laptop computer screen in this photo illustration in Athens, Greece, on February 9, 2026. Vaccine manufacturers play a central role in global public health, investing ...

The healthcare stock is up over 300% in five years and has a market cap of around $1 trillion.

Eli Lilly will make experimental retatrutide available before FDA approval to a limited group. The eligibility bar is high.